浙江仙琚制药股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 15 日召开的公司 2024 年年度股东大会审议通 过，现将权益分派事宜公告如下： 股票代码：002332 股票简称：仙琚制药 公告编号：2025-025 浙江仙琚制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次分派对象为：截止 2025 年 5 月 27 日下午深圳证券交易所收市后，在 中国证券登记结算有限责任公司深圳分公司（以下简称"中国结算深圳分公司"） 登记在册的本公司全体股东。 五、权益分派方法 年 5 月 28 日通过股东托管证券公司（或其他托管机构）直接划入其资金账户。 序号 股东账号 股东名称 一、 股东大会审议通过权益分派方案情况 度利润分配预案》：以 2024 年 12 月 31 日的总股本 989,204,866 股为基数， 向全体股东每 10 股派发现金红利人民币 3.00 元（含税）。2025 年度不送红股 也不以公积金转增股本。 变化，仍为 989,204,866 股。 案一致。 超过两个月。 二、 ...

股票代码：002332 股票简称：仙琚制药 公告编号：2025-025 浙江仙琚制药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 15 日召开的公司 2024 年年度股东大会审议通 过，现将权益分派事宜公告如下： 3、本次实施的利润分配方案与公司 2024 年度股东大会审议通过的分配方 案一致。 4、本次实施的利润分配方案距公司 2024 年度股东大会审议通过的时间未 超过两个月。 二、本次权益分派方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 989,204,866 股为 基数，向全体股东每 10 股派发现金红利人民币 3.00 元（含税；扣税后，通过 深股通持有股份的香港市场投资者、QFII、RQFII 以及持有首发前限售股的个 人和证券投资基金每 10 股派 2.70 元；持有首发后限售股、股权激励限售股及 无限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所 ...

Financial Performance - In 2024, the company achieved a revenue of CNY 4.0 billion, a year-on-year decline of 2.98%. The net profit attributable to shareholders was CNY 397 million, down 29.46% year-on-year [3] - In Q1 2025, the company reported a revenue of CNY 1.01 billion, a decrease of 2.86% year-on-year, with a net profit of CNY 144 million, down 4.7% year-on-year [3] - The formulation business generated CNY 2.42 billion in revenue in 2024, a growth of 6.0%, while the raw material business revenue was CNY 1.55 billion, down 13.4% [3] Product Performance - In Q1 2025, the sales revenue of the formulation segment was CNY 535 million, a decline of 6.6% [4] - Key product sales by therapeutic area included: - Gynecology and family planning: CNY 100 million, down 20% - Anesthesia and muscle relaxants: CNY 36 million, up 20% - Respiratory products: CNY 210 million, up 16% - Dermatology products: CNY 55 million, up 8% - Generic drugs: CNY 116 million, down 28% [4] R&D and Innovation - The company has established a comprehensive R&D system, increasing R&D investment from CNY 80 million in 2015 to CNY 265 million in 2024, with a R&D intensity rising from 3.5% to 6.6% [6][7] - New drug applications include: - Omalizumab sodium: submitted for approval in September 2024 - Improved new drug CZ1S: entered Phase III clinical trials in February 2025 [5] - The company is focusing on high-barrier complex formulations and has multiple key R&D projects in this area [5] Market Strategy - The company is implementing a "five-in-one" strategy for internationalization, focusing on macroeconomic conditions, market demand, entry barriers, competitive landscape, and its own advantages [11] - The company anticipates growth in foreign sales despite price fluctuations, aiming to expand market share and sales of new products [12] - The sales strategy is divided into three phases: stabilize, expand, and innovate, with a focus on maintaining market presence and exploring new fields [13] Future Outlook - The company plans to enhance its product lines in the steroid hormone sector, emphasizing long-term value creation and sustainable development [9][10] - The respiratory product, Mometasone nasal spray, is expected to be a significant revenue source, with continued growth anticipated in the coming years [8] - The company aims to strengthen its supply chain by extending upstream to optimize costs and enhance market competitiveness [17]

股票代码：002332 股票简称：仙琚制药 公告编号：2025-024 浙江仙琚制药股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议召开时间为：2025年5月15日下午14：30 网络投票时间为：2025年5月15日。其中，通过深圳证券交易所交易系统进行 网络投票时间为：2025年5月15日9:15-9:25，9:30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统开始投票的时间为：2025年5月15日9:15- 15:00。 2、现场会议召开地点：浙江仙琚制药股份有限公司会议室； 3、会议召集人：公司董事会； （二）会议的出席情况 1、出席会议股东总体情况 4、会议方式：本次股东大会采取现场投票和网络投票相结合的方式； 5、股权登记日：2025年5月12日； 6、现场会议主持人：公司董事长张宇松先生； 本次会议 ...

上海市锦天城律师事务所 关于浙江仙琚制药股份有限公司 2024 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江仙琚制药股份有限公司 2024 年年度股东大会的 法律意见书 致：浙江仙琚制药股份有限公司 （二）本次股东大会的召开 本次股东大会现场会议于 2025 年 5 月 15 日 14:30 在浙江省仙居县福应街道 现代工业集聚区丰溪西路 15 号浙江仙琚制药股份有限公司五楼会议室如期召开。 本次股东大会采取现场投票和网络投票相结合的方式召开。本次股东大会通 过深圳证券交易所系统进行网络投票的具体时间为 2025 年 5 月 15 日 9:15-9:25， 9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间 为 2025 年 5 月 15 日 9:15-15:00。 上海市锦天城律师事务所（以下简称"本所"）接受浙江仙琚制药股份有限 公司（以下简称"公司" ...

Core Viewpoint - Three pharmaceutical companies, Xianju Pharmaceutical, Tianjin Pharmaceutical, and Lianhuan Pharmaceutical, have been penalized for monopolistic practices related to the raw material dexamethasone sodium phosphate, with total fines amounting to approximately 325 million yuan [1][2][3]. Group 1: Penalties and Financial Impact - Xianju Pharmaceutical was fined a total of approximately 195 million yuan, which includes the confiscation of illegal gains of 23.74 million yuan and a fine of about 172 million yuan based on 8% of its 2023 sales [2][5]. - Tianjin Pharmaceutical faced penalties totaling approximately 69.19 million yuan, including the confiscation of illegal gains of 42.76 million yuan and a reduced fine of about 13.2 million yuan after an 80% reduction [3][5]. - Lianhuan Pharmaceutical was fined approximately 61.04 million yuan, which includes the confiscation of illegal gains of 17.89 million yuan and a reduced fine of about 61.63 million yuan after a 30% reduction [3][5]. Group 2: Profitability Impact - The fines significantly impact the profitability of the companies, with Tianjin Pharmaceutical's penalties representing 2.15% of its recent audited revenue and 51.85% of its net profit attributable to shareholders [5]. - For Xianju Pharmaceutical, the total fine of 195 million yuan accounts for 4.87% of its projected 2024 revenue of 4 billion yuan and 49.17% of its net profit of 397 million yuan [5]. - Lianhuan Pharmaceutical's proposed fines represent 72.53% of its net profit of 84 million yuan for the previous year [5]. Group 3: Recurrence of Violations - Tianjin Pharmaceutical has been penalized for monopolistic behavior for the fourth time in four years, with cumulative fines exceeding 170 million yuan [6][7].

每经记者｜甄素静 每经编辑｜文多 2021年末至2024年3月，四家公司因联合以垄断协议形式变更、固定地塞米松磷酸钠原料药价格，整个过程中，致使上述原料药售价从每公斤数千元提升至 每公斤上万元。近日，四家公司相继被处罚或收到行政处罚告知书，企业被罚及拟被罚金额合计超3.5亿元。 为何津药药业、联环药业可以减免部分罚款？记者了解到，主要是因为仙琚制药、西安国康瑞金在天津市市场监管委开展调查后，未提交宽大申请，不存在 宽大情节（西安国康瑞金在陈述申辩环节提出申辩意见，但未被采纳）。而津药药业在天津市市场监管委开展调查后，第一个提交宽大申请，公司报告了达 成垄断协议的有关情况并提供重要证据。 图片来源：视觉中国-VCG211188000714 郭某组织四家企业达成并实施垄断协议 据天津市市场监管委调查，在当事人郭某的组织下，具有竞争关系的津药药业、仙琚制药、联环药业和西安国康瑞金共同实施了违反"反垄断法"的违法行 为。 据悉，地塞米松磷酸钠原料药是生产地塞米松磷酸钠注射液的主要原材料。地塞米松磷酸钠注射液是一种肾上腺皮质激素类药，主要用于过敏性与自身免疫 性炎症性疾病，同时被证明对新冠肺炎重症病人具有疗效，该药因此 ...

文/梧桐兄弟 值得注意的是，因同一事项一并受罚的还有 津药药业（600488.SH）和联环药业（600513.SH） ，分别被罚 没6,919.24万元、6,103.82万元。 天津市市场监督管理委员会决定责令公司停止违法行为，对公司作出行政处罚如下：（一）没收违法所得人 民币23,746,680.00元。 （二）并处2023年销售额8%的罚款 171,550,232.22 元，以上罚没款合计人民币 195,296,912.22元。 近期，仙琚制药（002332）披露公告，公司收到天津市市场监督管理委员会下发的《行政处罚决定书》， 公司与具有竞争关系的其他经营者，以垄断协议形式变更、固定地塞米松磷酸钠原料药价格，排除限制了地 塞米松磷酸钠原料药销售领域的竞争， 违反了《中华人民共和国反垄断法》第十七条第(一)项的规定， 属 于达成并实施"固定或者变更商品价格"垄断协议的行为， 应当依据《反垄断法》第五十六条的规定依法追 究法律责任。 ...

今日焦点中国中车：近期签订合计547.4亿元重大合同 中国中车公告称，公司及下属企业于近期（主要为2024年12月至2025年5月）签订了若干项重大合同， 合计金额约547.4亿元人民币。主要合同包括城市轨道车辆、设备销售及维保合同，动车组销售合同， 动车组高级修合同，风电设备销售合同和储能设备销售合同，机车销售合同以及货车修理合同。上述合 同总金额约占公司中国会计准则下2024年营业收入的22.2%。 阳光诺和：拟购买朗研生命100%股权，股票明日复牌 南方财经5月12日电，阳光诺和(688621.SH)公告称，公司拟通过发行股份及可转换公司债券购买资产并 募集配套资金，购买利虔、朗颐投资等38名朗研生命股东持有的朗研生命100%股权。并向不超过35名 特定投资者发行股份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外 提供药品生产服务，在高端化学药、原料药等领域深耕多年，已经形成了较为成熟的医药生产体系。公 司股票将于5月13日开市起复牌。 沃尔核材：筹划发行H股股票并申请在香港联交所主板上市 沃尔核材公告称，公司拟发行H股股票并申请在香港联交所主板挂牌上市，以推进国际化战略，提升 ...

Company Announcements - Zhaowei Electromechanical plans to reduce its shareholding by no more than 1.5%, equating to approximately 3.6 million shares [1] - China CNR Corporation has signed several major contracts totaling approximately 54.74 billion yuan, representing about 22.2% of its expected revenue for 2024 [2] - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a temporary suspension of its stock [2] - Sunshine Nuohua intends to acquire 100% of Langyan Life, with its stock set to resume trading [3] - Wolong Materials is planning to issue H-shares and apply for a listing on the Hong Kong Stock Exchange [3] - Hanyu Pharmaceutical has signed a joint development agreement for a novel peptide drug targeting metabolic diseases [3] - Lijun Co. confirms that its operations are normal and there are no undisclosed significant matters [3] Investments & Acquisitions - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [4] - Shuangyi Technology intends to acquire 100% of Marky Industries for 18 million AUD, along with specific assets [5] Strategic Partnerships - Sileck has signed a strategic cooperation agreement with Lihua Power for the development of large cylindrical batteries [6] - Hongchang Technology plans to invest 15 million yuan in a humanoid robot industry chain company [7] - Macroview Technology is establishing a wholly-owned subsidiary focused on artificial intelligence [8] - Yihua Jiaye has signed a strategic cooperation framework agreement with Hanyu Pharmaceutical and Hanyu Health to develop a sleep health ecosystem [9] - Wanda Film is investing in Lezi Tiancheng and will engage in strategic cooperation in IP toy product development [10] Shareholding Changes - Tiandi Online's controlling shareholder is transferring 6.97% of its shares to introduce a strategic investor [12] - Longjiang Transportation plans to reduce its shareholding by no more than 3% [13] - Boyun New Materials intends to reduce its shareholding by no more than 3% [14] - Tongrun Equipment's major shareholder plans to reduce its stake by no more than 2% [15] Financing & Capital Increase - Tangyuan Electric plans to raise no more than 864 million yuan through a private placement [16] - Shangsheng Electronics intends to issue convertible bonds to raise up to 330 million yuan [17] Other Developments - Xianju Pharmaceutical has obtained a domestic production registration certificate for Dydrogesterone tablets [18] - Rongchang Bio has received a clinical trial application acceptance notice for its antibody-drug conjugate RC278 [19] - Jiangsu Leili's subsidiary Dingzhi Technology is implementing a stock incentive plan [20]